The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia.
Facility: Research Medical Center

CLL 39: A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

CLL 41: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy.
Facility: Menorah Medical Center, Research Medical Center

LYM 120: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 122: A phase 3, randomized, double blind, placebo controlled, multicenter study of BR alone versus in combination with Acalabrutinib (ACP-196) in subjects with previously untreated mantle cell Lymphoma, radiologically measurable lymphadenopathy or extranodal lymphoid malignancy.
Facility: Menorah Medical Center, Research Medical Center

LYM 126: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma.
Facility: Menorah Medical Center, Research Medical Center

MM 61: A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM).
Facility: Menorah Medical Center, Research Medical Center

MM 74: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

PREAMBLE:

Prospective research assessment in multiple myeloma: an observational evaluation (preamble). PI: Jaswinder Singh, MD


Facility: Research Medical Center

BRE 261:

A Phase Ib, Open-Label, Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with: Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Doxorubicin with Cyclophoshamide in HER2-Negative Breast Cancer. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 263: The impact of HER2 heterogeneity on the treatment of early-stage HER2-positive breast cancer: a phase II study of T-DM1 in combination with Pertuzumab in the preoperative setting. PI: Stephanie Graff, MD
Facility: Menorah Medical Center

BRE 274: A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 293:

A phase III randomized study to investigate the efficacy and safety of atezolizumab (anti-pd-l1 antibody) in combination with neoadjuvant anthracycline-based chemotherapy compared with placebo and chemotherapy in patients with primary invasive triple-negative breast cancer. PI: Stephanie Graff, MD


Facility: Menorah Medical Center, Research Medical Center

BRE 296:

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. PI: Stephanie Graff, MD


Facility: Menorah Medical Center, Research Medical Center

  :  
Facility:  

GI 201 - INN: A Phase II Study of Nab-paclitaxel plus Ramucirumab for the Second-line Treatment of Patients with Metastatic Gastroesophageal Cancer. PI: Jaswinder Singh, MD
Facility: Research Medical Center

GI 221: A phase 2 study of lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors undergoing liver-directed radioembolization with yttrium-90 microspheres (SIR-Spheres). PI: Jaswinder Singh, MD
Facility: Menorah Medical Center, Research Medical Center

GI 247: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer
Facility: Menorah Medical Center, Research Medical Center

GI 250: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
Facility: Menorah Medical Center, Research Medical Center

GU 118: An Open-Label, Non-randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 135: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemo-therapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 136: Phase IIIb/IV Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 137: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 139: A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (antiƒ{pd-l1 antibody) in combination with Enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen.
Facility: Menorah Medical Center, Research Medical Center

GU 142: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 144:

A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable/Locally Advanced or Metastatic Papillary Renal Cell Carcinoma. PI: Peter Van Veldhuizen, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 147: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind study of Atezolizumab (Anti-PD-L1 antibody) as adjuvant therapy in patients with PD-L1 selected renal cell carcinoma at intermediate to high risk of developing metastasis following nephrectomy.
Facility: Menorah Medical Center, Research Medical Center

GU 148: A phase III, randomized, double-blind, placebo-controlled, multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/ prednisolone in patients with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer with pten-loss (pten diagnostic positive) tumors.
Facility: Menorah Medical Center, Research Medical Center

GU 150:

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC). PI: Peter Van Veldhuizen, MD


Facility: Menorah Medical Center, Research Medical Center

MULTI 26:

A Phase II, Open-label, multicenter, multicohort study to investigate the efficacy and safety of Cobimetinib plus Atezolizumab in patient with solid tumors. PI: Peter Van Veldhuizen, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN 41: A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. PI: Kristopher LyBarger, MD
Facility: Research Medical Center

GYN 63: A Phase II Open-Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Acelarin® (NUC-1031) Given on Days 1, 8 and 15 of a 28-Day Schedule in Patients with Recurrent Platinum-Resistant Ovarian Cancer.
Facility: Centerpoint Medical Center, Research Medical Center

GYN 66: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation. PI: Kristopher LyBarger, MD
Facility: Research Medical Center

GYN 70: A Randomized, Placebo-controlled, Double blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients with Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment with a Safety Lead-in.
Facility: Research Medical Center

GYN 72: A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer.
Facility: Research Medical Center

REFMAL 365: A Phase Ib Study evaluating the c-Met Inhibitor INC280 in Combination with Bevacizumab in Glioblastoma Multiforme (GBM), Patients. PI: Amandeep Kalra, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 349: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).
Facility: Menorah Medical Center, Research Medical Center

LUN 350:

A Phase 3 Randomized, Open Label Efficacy and Safety Study of Lorlatinib Monotherapy vs Crizotinib Monotherapy in 1st Line Treatment of ALK-positive NSCLC. PI: Joseph Stilwill, MD


Facility: Menorah Medical Center, Research Medical Center

LUN 356: A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Small-Cell Lung Cancer (SCLC) Patients Receiving First-Line Standard of Care Platinum-Based Chemotherapy.
Facility: Menorah Medical Center, Research Medical Center

LUN 358-NSC:

Prospective, randomized, multicenter, open-label, comparative global phase 3 study to determine the efficacy, safety and tolerability of durvalumab or durvalumab + tremelimumab in combination therapy with platinum based chemotherapy for the firstline treatment of patients with metastatic non small-cell lung cancer. PI: Joseph Stilwill, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MEL 54: A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus Cobimetinib and vemurafenib in previously untreated brafv600 mutation−positive patients withunresectable locally advanced or Metastatic melanoma.
Facility: Menorah Medical Center, Research Medical Center